<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of vitamin E</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of vitamin E</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of vitamin E</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sassan Pazirandeh, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David L Burns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Seres, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sara Swenson, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vitamins are a number of chemically unrelated families of organic substances that cannot be synthesized in the human body but need to be ingested in the diet in small quantities to prevent disorders of metabolism. They are divided into water-soluble and fat-soluble vitamins (<a class="graphic graphic_table graphicRef63827" href="/d/graphic/63827.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> is a fat-soluble compound and protects cell membranes from oxidation and destruction.</p><p>In 1922, Evans and Bishop discovered that rats fed a lard-based diet developed infertility, suggesting a dietary deficiency [<a href="#rid1">1</a>]. The fertility was corrected when a lipid extract of cereals was added to the diet; this was termed the "anti-sterility factor" [<a href="#rid2">2</a>]. In 1925, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> was officially recognized as the fifth vitamin. A few years later, the name tocopherol, from the Greek word of "toc" (child) and "phero" (to bring forth), was coined to describe its role as an essential dietary substance in normal fetal and childhood development [<a href="#rid3">3</a>]. In 1969, the US Food and Drug Administration (FDA) formally recognized vitamin E as an essential nutrient for humans.</p><p>This topic review will focus on <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>. Overviews of the other fat-soluble vitamins, minerals, and water-soluble vitamins are available elsewhere. (See  <a class="medical medical_review" href="/d/html/2571.html" rel="external">"Overview of vitamin A"</a> and  <a class="medical medical_review" href="/d/html/2033.html" rel="external">"Overview of vitamin D"</a> and  <a class="medical medical_review" href="/d/html/2624.html" rel="external">"Overview of vitamin K"</a> and  <a class="medical medical_review" href="/d/html/2585.html" rel="external">"Overview of dietary trace elements"</a> and  <a class="medical medical_review" href="/d/html/5367.html" rel="external">"Overview of water-soluble vitamins"</a> and  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SOURCES</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> is found in a variety of foods including almonds, vegetable oils, and cereals. The form that is best known for its role in human health is alpha-tocopherol, which is abundant in olive and sunflower oils and is the predominant form in the European diet. Gamma-tocopherol is another form, which is abundant in soybean and corn oil and is common in the American diet.</p><p><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> is also available in supplements, either alone or as part of a multivitamin supplement.</p><p class="headingAnchor" id="H3"><span class="h1">CHEMISTRY AND NOMENCLATURE</span><span class="headingEndMark"> — </span>The primary bioactive form of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> is alpha-tocopherol. Alpha-tocopherol has eight isomers, but only four of these (RRR-, RSR-, RRS-, and RSS-alpha-tocopherol) are efficiently maintained in human plasma, and these are the forms to which the dietary reference intakes apply [<a href="#rid4">4</a>]. Furthermore, the RRR-isomer (formerly and incorrectly called D-alpha-tocopherol) is the only form found in foods; it is sometimes known as "natural source" vitamin E.</p><p>Many synthetic <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplements or fortified foods contain all eight isomers of alpha-tocopherol; these are known as "all-racemic" or "DL" alpha-tocopherol and have approximately one-half of the activity of "natural source" vitamin E. However, all of the isomers of alpha-tocopherol may contribute to the potential adverse effects of supplemental vitamin E and are included in the calculation of an upper limit for supplementation [<a href="#rid4">4</a>].</p><p><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> dosing is quantified by the content of the active isomer:</p><p>1 mg RRR-alpha-tocopherol</p><p class="bulletIndent1">= 1.49 international units "natural source" <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (D-alpha-tocopherol)</p><p class="bulletIndent1">= 2.22 international units "all-racemic" <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (DL-alpha-tocopherol)</p><p></p><p>Seven other naturally occurring <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> compounds have been described: beta-, gamma-, and delta-tocopherol and alpha-, beta-, gamma-, and delta-tocotrienols. Nutrient databases, especially older data sources, often report either total tocopherol concentrations or "alpha-tocopherol equivalents," which adjust for the bioavailability for the various forms [<a href="#rid4">4</a>]. However, these measures do not reflect the bioactivity of alpha-tocopherol, which is now used as the standard for dietary sufficiency.</p><p>Gamma-tocopherol is transported less efficiently and has lower plasma levels than alpha-tocotrienols, but tissue levels are similar [<a href="#rid5">5</a>]. Because gamma-tocopherol is associated with alterations in levels of inflammation and airway hyperresponsiveness (see <a class="local">'Actions'</a> below), this compound may have important adverse or beneficial effects, although it is not included in the recommended daily allowance (RDA). Pharmacologic doses of alpha-tocopherol taken in supplements reduce levels of gamma-tocopherol in plasma [<a href="#rid5">5,6</a>].</p><p>In most reports and in this topic review, the term "<a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>" refers to the biologically active isomers of alpha-tocopherol, unless otherwise specified.</p><p class="headingAnchor" id="H4"><span class="h1">ACTIONS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> (as alpha-tocopherol) works as a free radical scavenger, protecting polyunsaturated fatty acids, a major structural component of the cell membranes, from peroxidation [<a href="#rid7">7</a>]. In the past few decades, there has been increasing interest in the role of free radicals and antioxidants in atherosclerosis and carcinogenesis. Deficiency of vitamin E has been connected to cardiovascular events. Low-density lipoprotein (LDL) plays a central role in these hypotheses. When LDL is exposed to oxidative stress, it undergoes a cascade of changes affecting the vascular endothelium, thereby facilitating atherogenesis [<a href="#rid8">8-10</a>]. This theory is referred to as the oxidative modification hypothesis and has fueled epidemiologic studies and clinical trials in cardiology to determine the role of antioxidants, such as vitamin E, in prevention and treatment of atherosclerotic cardiovascular disease [<a href="#rid11">11</a>]. However, trials of vitamin E supplementation (which typically use "all-racemic" vitamin E) have generally shown no effect in prevention of heart disease. (See <a class="local">'Potential benefits'</a> below and  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention"</a>.)</p><p>Gamma-tocopherol appears to promote eosinophilic lung inflammation and airway hyperresponsiveness [<a href="#rid12">12,13</a>], although it also may oppose neutrophil-mediated inflammation, mediated by reductions in prostaglandin E2 [<a href="#rid14">14,15</a>]. The overall health effects of gamma-tocopherol have not been established. High doses of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (as alpha-tocopherol) reduce levels of gamma-tocopherol, perhaps explaining the adverse effects of pharmacologic doses of the vitamin [<a href="#rid5">5,6</a>].</p><p>Some functions of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> are independent of the antioxidant/radical scavenging activity, including inhibition of cell proliferation, platelet aggregation, and monocyte adhesion [<a href="#rid16">16</a>]. Several other effects at the molecular level have been identified, but the clinical implications of these actions have not been established.</p><p class="headingAnchor" id="H5"><span class="h1">METABOLISM</span><span class="headingEndMark"> — </span>Like other fat-soluble vitamins, bioavailability of alpha-tocopherol depends upon physiologic mechanisms of fat digestion and absorption. This process requires lingual and gastric lipases; bile salts for solubilization and production of mixed micelles; pancreatic function; and intestinal and ileal mucosal and absorptive mechanisms. Bile salts and pancreatic enzymes are particularly important for intraluminal digestion of fat [<a href="#rid17">17</a>]. Pancreatic esterases are the enzymes responsible for breaking down the tocopheryl-ester bonds between alpha-tocopherol and fatty acids [<a href="#rid18">18</a>]. Within the intestinal mucosal cells, chylomicrons are produced from phospholipids, triglycerides, apolipoproteins, and fat-soluble vitamins. The synthesis of chylomicrons is required for transport of alpha-tocopherol via the lymphatic system to the liver [<a href="#rid19">19</a>]. Within hepatocytes, chylomicron remnants are broken down by lysosomes, and RRR-alpha-tocopherol is preferentially secreted into the bloodstream, packaged within very low-density lipoprotein molecules [<a href="#rid20">20</a>]. The transport protein for alpha-tocopherol is named alpha-tocopherol transfer protein [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H6"><span class="h1">REQUIREMENTS</span><span class="headingEndMark"> — </span>Dietary <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> content is variable and proportional to vegetable oil intake. American diets of 2000 to 3000 kcal/day contain 7 to 10 mg of alpha-tocopherol equivalents. However, this is likely an underestimate because dietary fat intake is commonly underreported.</p><p class="headingAnchor" id="H26561062"><span class="h2">Healthy population</span><span class="headingEndMark"> — </span>The recommended daily allowance (RDA) for <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> is 15 mg of dietary alpha-tocopherol for adolescents and adult males and females, as defined by the United States National Academy of Sciences Food and Nutrition Board [<a href="#rid4">4</a>]. This is the equivalent of 22 international units of RRR-alpha-tocopherol (the form that is supplied by some supplements and is marketed as "natural source" vitamin E) or 33 international units of "all-racemic" alpha-tocopherol (the synthetic form used for the majority of supplements) [<a href="#rid4">4</a>]. In children, the RDA rises from 6 mg at 1 to 3 years of age to 15 mg by 14 to 18 years (<a class="graphic graphic_table graphicRef81151" href="/d/graphic/81151.html" rel="external">table 2</a>). Note that although the requirements are stated in terms of alpha-tocopherol equivalents, a substantial portion of this will be provided as gamma-tocopherol if dietary sources are used. For this reason, dietary vitamin E may have advantages over vitamin E taken as a supplement. (See <a class="local">'Chemistry and nomenclature'</a> above and <a class="local">'Actions'</a> above.)</p><p class="headingAnchor" id="H26561069"><span class="h2">Patients with fat malabsorption</span><span class="headingEndMark"> — </span>Patients with fat malabsorption are at risk for <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency because of malabsorption of fat and fat-soluble vitamins; in most cases, this is caused by a pancreatic, hepatic, or intestinal disorder. Rarely, vitamin E deficiency is caused by a genetic disorder that affects vitamin E transport. (See <a class="local">'Causes'</a> below.)</p><p>For patients with pancreatic insufficiency due to cystic fibrosis, guidelines recommend routine supplements with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> and other fat-soluble vitamins. Dosing and monitoring are discussed separately. Similar strategies are likely to be appropriate for patients with other causes of severe pancreatic exocrine insufficiency. (See  <a class="medical medical_review" href="/d/html/5882.html" rel="external">"Cystic fibrosis: Nutritional issues", section on 'Fat-soluble vitamins'</a>.)</p><p>Prevention and management of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency depends upon the severity of the fat malabsorption, as discussed below. (See <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h1">DEFICIENCY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> deficiency is uncommon in humans except in unusual circumstances. This is due to the abundance of tocopherols in a wide variety of diets, including vegetarian and vegan diets. It occasionally occurs in individuals with severe protein-energy malnutrition [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H3459898355"><span class="h2">Causes</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> deficiency is most commonly seen in patients with medical conditions that cause fat malabsorption. The degree of deficiency is generally proportional to the magnitude and duration of steatorrhea. Important causes of fat malabsorption are:</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic exocrine insufficiency – In which there is insufficient lipase to enable optimal fat absorption. Important causes are cystic fibrosis, pancreatectomy, and chronic pancreatitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cholestatic liver disease – In which there is insufficient bile in the intestinal lumen to permit fat solubilization and absorption. Important causes include biliary atresia, primary sclerosing cholangitis, primary biliary cholangitis, and familial intrahepatic cholestasis. Fat malabsorption may also occur in other types of cirrhosis, although typically late in the course of the liver disease (decompensated cirrhosis). Patients with cholestasis also tend to have hyperlipidemia, which influences <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> levels, so assessment of their vitamin E status requires simultaneous measurement of alpha-tocopherol and serum lipids. (See <a class="local">'Measurement'</a> below.)</p><p></p><p class="bulletIndent1">Although cholestasis is a risk factor for fat-soluble vitamin deficiencies, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency is uncommon except in patients with severe and prolonged cholestasis. Most cases arise in patients with severe and prolonged primary biliary cholangitis, typically in those with cirrhosis and hyperbilirubinemia [<a href="#rid23">23-26</a>]. However, it is considerably less common than other fat-soluble vitamin deficiencies [<a href="#rid26">26</a>]. For patients with significant cholestasis (eg, bilirubin &gt;2 mg/dL), routine monitoring of fat-soluble vitamin levels is recommended, although deficiencies of vitamin E are uncommon [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive resection or disease affecting small intestine – In which there is insufficient intestinal absorptive area to permit fat absorption. If there is loss or disease of the terminal ileum, this may also cause malabsorption of bile acids and a diminished bile acid pool, which further contributes to fat malabsorption. Important causes include short bowel syndrome, congenital intestinal lymphangiectasia, infiltrative diseases such as amyloid or lymphoma, and Crohn disease.</p><p></p><p>Patients with these conditions typically require high maintenance doses of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>. (See <a class="local">'Patients with fat malabsorption'</a> above.)</p><p>There are also several genetic disorders that lead to <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Ataxia with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency, due to a mutation in the gene encoding hepatic alpha-tocopherol transfer protein (<em>TTPA</em>). Affected patients have neurologic deficits including symptoms similar to Friedreich ataxia [<a href="#rid28">28</a>]. These patients sometimes respond to oral supplementation of vitamin E in doses of 800 to 1500 mg/day (1200 to 2200 international units/day) of alpha-tocopherol for adults or 40 mg/kg/day (60 international units/kg/day) for children [<a href="#rid29">29-32</a>]. More often, supplementation serves to prevent progression of the disease [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Treatable diseases'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abetalipoproteinemia, due to mutations in the microsomal triglyceride transfer protein. This disorder is characterized by very low or absent levels of low-density lipoprotein (LDL) and fat-soluble vitamin deficiencies. Symptoms may include progressive ataxia, sensory-motor neuropathy, and vision impairment with retinitis pigmentosa. Less severe deficits of LDL and fat-soluble vitamins are seen in hypobetalipoproteinemia. (See  <a class="medical medical_review" href="/d/html/14122.html" rel="external">"Neuroacanthocytosis", section on 'Abetalipoproteinemia'</a> and  <a class="medical medical_review" href="/d/html/107473.html" rel="external">"Low LDL-cholesterol: Etiologies and approach to evaluation", section on 'Homozygous familial hypobetalipoproteinemia'</a> and  <a class="medical medical_review" href="/d/html/107473.html" rel="external">"Low LDL-cholesterol: Etiologies and approach to evaluation", section on 'Abetalipoproteinemia'</a>.)</p><p></p><p class="headingAnchor" id="H4250359426"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>In adults and children, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency can cause neuromuscular disorders and hemolysis. Low serum levels of vitamin E (defined as below 0.5 mg/dL) may cause no appreciable symptoms or may manifest as subtle neurologic abnormalities. Neuromuscular disorders associated with vitamin E deficiency are mostly of the neuropathic and myopathic type [<a href="#rid33">33</a>]. The neuropathy generally consists of a spinocerebellar syndrome, with variable involvement of the peripheral nerves. Clinical manifestations include ataxia, hyporeflexia, and loss of proprioceptive and vibratory sensation [<a href="#rid34">34</a>]. A skeletal myopathy and pigmented retinopathy may also be present [<a href="#rid34">34</a>]. Brown bowel syndrome (intestinal lipofuscinosis) is a brown pigmentation of the bowel that occasionally presents with bowel dilatation and pseudo-obstruction [<a href="#rid35">35,36</a>]. It is a rare complication of chronic vitamin E deficiency and is thought to be caused by lipofuscin accumulation within the smooth muscle mitochondria.</p><p><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> deficiency can shorten the lifespan of red blood cells. In premature infants, vitamin E deficiency may cause a hemolytic anemia [<a href="#rid37">37</a>]. Congenital hemolytic disorders such as thalassemia, sickle cell anemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, and spherocytosis may be associated with low vitamin E plasma levels, likely because of increased oxidant stress and antioxidant consumption [<a href="#rid38">38-40</a>]. Oral therapy with vitamin E supplementation may be of benefit, but efficacy has not been proven [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H9970551"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Patients with documented <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency should be treated with large oral doses of vitamin E.</p><p>For infants and children with cholestasis, typical supplementation regimens are 17 to 35 mg/kg/day of RRR-alpha-tocopherol (25 to 50 international units/kg/day of RRR-alpha-tocopherol, or "natural source" <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>) [<a href="#rid43">43,44</a>]. If this form is used, some patients may require incremental increases up to 70 to 130 mg/kg/day (100 to 200 international units/kg/day) to achieve normal serum measurements of alpha-tocopherol (or ratio of alpha-tocopherol/total lipids).</p><p>Water-miscible <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> (RRR-alpha-tocopherol polyethylene glycol 1000 succinate [TPGS]) also may be used; typical doses for cholestatic conditions are 10 to 17 mg/kg/day (15 to 25 international units/kg/day) [<a href="#rid45">45</a>]. TPGS is available as an over-the-counter nutritional supplement in the United States (brand names: DEKAs [provides multiple fat-soluble vitamins], Aqua-E), but no pharmaceutical-grade preparation is approved by the US Food and Drug Administration (FDA). A pharmaceutical-grade form of TPGS (Vedrop) is available in Europe. TPGS may be more effective than other types of vitamin E supplements for treatment of some of the most severe chronic cholestatic conditions, such as Alagille syndrome, biliary atresia, and progressive familial intrahepatic cholestasis [<a href="#rid45">45</a>].</p><p>For adults with fat malabsorption due to cholestasis, pancreatic insufficiency, or intestinal disease or resection, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> requirements are variable. If vitamin E replacement is needed, doses are typically started at 50 to 500 mg/day (75 to 800 international units/day), then adjusted as needed to achieve normal serum measurements of alpha-tocopherol (or ratio of alpha-tocopherol/total lipids), assuming that albumin levels are normal. (See <a class="local">'Measurement'</a> below.)</p><p>Patients with severe cholestasis or genetic disorders that interfere with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> transport might not respond to even high doses of oral alpha-tocopherol. Intramuscular vitamin E is effective, but it is not widely available and is somewhat impractical as it requires frequent (weekly) dosing [<a href="#rid46">46</a>]. (See <a class="local">'Causes'</a> above.)</p><p class="headingAnchor" id="H3420886772"><span class="h1">MEASUREMENT</span></p><p class="headingAnchor" id="H1241441434"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Monitoring of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> status is not necessary in healthy patients but is appropriate for patients with risk factors for vitamin E deficiency, which include (see <a class="local">'Causes'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic cholestatic liver disease such as primary biliary cholangitis or primary sclerosing cholangitis when disease is in its advanced stage (eg, bilirubin &gt;2 mg/dL).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Severe cholestatic diseases (mostly in pediatrics) such as Alagille syndrome and biliary atresia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic exocrine insufficiency (patients with steatorrhea due to chronic pancreatitis or cystic fibrosis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive disease or resection of the small intestine (eg, patients with short bowel syndrome, those who have had gastric bypass surgery, and selected patients with Crohn disease).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with unexplained spinocerebellar neuropathy or ataxia. These symptoms may be caused by severe nutritional deficiency or acquired or hereditary malabsorption of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>. (See  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Treatable diseases'</a>.)</p><p></p><p>If <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency is identified, the patient should be treated with high-dose supplements. (See <a class="local">'Treatment'</a> above.)</p><p class="headingAnchor" id="H3488885603"><span class="h2">Method</span><span class="headingEndMark"> — </span>For patients with normal levels of serum lipids and carrier proteins, serum alpha-tocopherol levels provide an adequate estimate of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> sufficiency. Alpha-tocopherol levels of less than 0.5 mg/dL (5 mcg/mL or 11.5 micromol/L) are considered deficient. In a United States national survey, the 5<sup>th</sup> percentile for serum levels of vitamin E was 0.62 mg/dL (14.3 micromol/L) and the 25<sup>th</sup> percentile was 0.79 mg/dL (18.5 micromol/L) [<a href="#rid4">4</a>].</p><p>For patients with marked hyperlipidemia, the serum <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> level does not accurately reflect tissue vitamin levels. In these patients, the patient's vitamin E status can be estimated using the following ratio [<a href="#rid47">47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Effective serum <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> level = alpha-tocopherol (mg) / total lipids (g)</p><p></p><p class="bulletIndent1">Where total lipids = cholesterol + triglycerides.</p><p></p><p>A normal result is &gt;0.8 mg.</p><p>Low levels of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> should be interpreted with caution in hypoproteinemic states because fat-soluble vitamins are transported bound to carrier proteins. We are not aware of data that define target levels from which to determine sufficiency in the hypoproteinemic state. Further, estimates of adequacy based on blood levels do not account for populations with low carrier protein levels.</p><p class="headingAnchor" id="H8"><span class="h1">RISKS AND BENEFITS OF SUPPLEMENTATION</span></p><p class="headingAnchor" id="H982588039"><span class="h2">Potential risks</span><span class="headingEndMark"> — </span>For adults without fat malabsorption, the tolerable upper intake level (UL) is 1000 mg/day for any form of alpha-tocopherol (approximately 1500 international units of "natural source" or 2200 international units of synthetic <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>). The UL in children rises from 200 mg/day at 1 to 3 years to 600 mg/day at 9 to 13 years (<a class="graphic graphic_table graphicRef81151" href="/d/graphic/81151.html" rel="external">table 2</a>). These ULs are based primarily on concerns for hemorrhagic effects [<a href="#rid4">4</a>]. We do not recommend supplementation near this level except when necessary to correct a deficiency state.</p><p>While pharmacologic doses of up to 270 mg/day RRR-alpha-tocopherol (400 international units/day of "natural source" <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a>) are probably safe for most patients, we recommend supplementation doses remain below this level. Some meta-analyses suggest that doses above this range may increase all-cause mortality, although these analyses are limited because the trials of high-dose vitamin E were small and most included patients with chronic diseases [<a href="#rid48">48,49</a>]. Other studies suggested doses at or above this range significantly increase the risk for prostate cancer [<a href="#rid50">50</a>]. Therefore, we suggest that doses in this range be used only for patients with specific indications, such as selected patients with nonalcoholic fatty liver disease or age-related macular degeneration, as outlined below. Patients without special indications should not take vitamin E supplements for disease prevention. (See <a class="local">'Potential benefits'</a> below and  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Vitamin E'</a>.)</p><p>Theoretical concerns have been raised that <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation might increase the risk for operative bleeding because vitamin E is known to inhibit platelet aggregation and adhesion in vitro [<a href="#rid51">51</a>]. However, studies in humans give no evidence that supplements (eg, 500 mg [800 international units]/day) prolong bleeding propensity or alter platelet aggregation in the absence of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> or anticoagulant therapy [<a href="#rid52">52,53</a>]. Other studies caution against the use of vitamin E in patients with an increased propensity to bleeding or those taking aspirin or vitamin K antagonist anticoagulants such as <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> [<a href="#rid54">54,55</a>]. In animal models, high-dose vitamin E supplements impaired absorption of fat-soluble vitamins A and K [<a href="#rid56">56</a>]. Large oral supplements of vitamin E have been associated with necrotizing enterocolitis in infants [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Potential benefits</span><span class="headingEndMark"> — </span>Diseases for which high-dose <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation may be beneficial for selected patients are:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonalcoholic fatty liver disease</strong> – High-dose <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation may be beneficial for selected patients with nonalcoholic fatty liver disease. Studies have suggested improvements in aminotransferase abnormalities and/or some histologic outcomes, although long-term benefits on disease outcomes have not been demonstrated. (See  <a class="medical medical_review" href="/d/html/3600.html" rel="external">"Management of nonalcoholic fatty liver disease in adults", section on 'Potential pharmacologic therapies'</a> and  <a class="medical medical_review" href="/d/html/115661.html" rel="external">"Metabolic dysfunction-associated steatotic liver disease in children and adolescents", section on 'Pharmacotherapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age-related macular degeneration</strong> – For patients with established age-related macular degeneration, supplementation with antioxidant vitamins and zinc appears to delay progression of the disease [<a href="#rid58">58</a>]. Supplements for this purpose provide 400 international units of synthetic alpha-tocopherol (approximately 180 mg), which is generally considered safe, although higher doses may be associated with complications (see <a class="local">'Potential risks'</a> above). There is no evidence that supplementation with <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> or other antioxidant vitamins is effective for prevention of this disorder [<a href="#rid59">59</a>].</p><p></p><p><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> supplementation is probably not beneficial for the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiovascular disease</strong> – A benefit of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation in preventing cardiovascular disease appears to be unlikely. (See  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cancer</strong> – <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> supplementation has been evaluated for prevention of prostate cancer and several other common neoplasms. A benefit seems unlikely, and there is some evidence that supplementation may actually increase the risk for prostate cancer. (See  <a class="medical medical_review" href="/d/html/6949.html" rel="external">"Chemoprevention strategies in prostate cancer", section on 'Vitamin E'</a> and  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention", section on 'Cancer'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Premature infants</strong> – In premature infants, hemolytic anemia is a common abnormality encountered in the presence of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency [<a href="#rid37">37</a>]. Vitamin E therapy at standard doses slightly increases hemoglobin concentrations and reduces the incidence of periventricular hemorrhage [<a href="#rid60">60</a>]. However, the risk of sepsis also was increased with high-dose supplementation, regardless of whether administered by intravenous or oral routes. A few studies suggest some benefit in preventing retinopathy of prematurity, but overall the evidence is inconclusive [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/111238.html" rel="external">"Retinopathy of prematurity (ROP): Treatment and prognosis", section on 'Prevention'</a> and  <a class="medical medical_review" href="/d/html/5026.html" rel="external">"Parenteral nutrition in premature infants", section on 'Vitamins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dementia</strong> – Some studies suggest some association between development of Alzheimer disease and <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency [<a href="#rid61">61</a>]. Randomized trials suggest that high-dose vitamin E supplementation does not affect the risk of cognitive impairment or dementia but may slow progression of Alzheimer disease [<a href="#rid62">62</a>]. (See  <a class="medical medical_review" href="/d/html/5368.html" rel="external">"Vitamin intake and disease prevention"</a> and  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Antioxidants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tardive dyskinesia</strong> – Limited evidence suggests that <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation probably does not improve symptoms of tardive dyskinesia induced by neuroleptic medications [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/4908.html" rel="external">"Tardive dyskinesia: Prevention, treatment, and prognosis", section on 'Initial management'</a>.)</p><p></p><p class="headingAnchor" id="H811983305"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110557.html" rel="external">"Society guideline links: Vitamin deficiencies"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">Vitamin E</a> (tocopherol) is a fat-soluble vitamin with antioxidant properties; it protects cell membranes from oxidation and destruction. Vitamin E is found in a variety of foods including oils, meat, eggs, and leafy vegetables. (See <a class="local">'Requirements'</a> above and <a class="local">'Actions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are multiple forms and isomers of tocopherol and the related compounds, tocotrienols. The best evidence suggests that the primary bioactive form of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> is alpha-tocopherol. This is quantified according to the presence of the RRR-isomer, which is the only form found in nature and is also called "natural source" vitamin E or D-alpha-tocopherol. Synthetic vitamin E contains seven other isomers (termed "all-racemic" vitamin E or DL-alpha-tocopherol) and has lower activity and possibly more toxic potential than the RRR-isomer. (See <a class="local">'Chemistry and nomenclature'</a> above and <a class="local">'Actions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Measurement of serum alpha-tocopherol concentrations provides an accurate measure of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> status for most patients in the absence of hyperlipidemia. For patients with hyperlipidemia, effective vitamin E levels are calculated as the ratio of serum alpha-tocopherol per gram total lipids. (See <a class="local">'Measurement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gamma-tocopherol is also present in foods. It is transported less efficiently and has lower plasma levels than alpha-tocopherol, but similar tissue levels are achieved. The overall health effects of gamma-tocopherol have not been established.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absorption of dietary <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> requires fully functional mechanisms for fat absorption, including lingual and gastric lipases; bile salts for solubilization and production of mixed micelles; pancreatic function; and intestinal and ileal mucosal and absorptive mechanisms, unless provided in a synthetic water-soluble form. In addition, a specific protein (alpha-tocopherol transfer protein) is required for effective transport and use. (See <a class="local">'Metabolism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Signs and symptoms of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency include hemolysis, neuromuscular disorders, ataxia, and peripheral neuropathy. Because of an abundance of tocopherols in the human diet, vitamin E deficiency is rare except in individuals with cholestatic liver disease, pancreatic insufficiency, or other conditions causing substantial fat malabsorption or protein-energy malnutrition. Vitamin E deficiency also may be caused by rare genetic defects affecting vitamin E metabolism or transport. (See <a class="local">'Deficiency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>No syndrome of acute <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> toxicity has been described. In premature infants, high-dose vitamin E treatment was associated with increased risk for sepsis. Chronic intake of supplements of pharmacologic doses in excess of 270 mg/day RRR-alpha-tocopherol (400 international units/day) has been associated with increased risk of all-cause mortality and possibly prostate cancer. (See <a class="local">'Potential risks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is no evidence that supplementation of <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> improves health outcomes in healthy children or adults. We suggest that patients without special indications avoid taking daily supplements containing high doses (≥400 international units) of vitamin E (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Potential risks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with severe pancreatic insufficiency or cholestatic liver disease may have <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> deficiency due to fat malabsorption. For these individuals, we recommend vitamin E supplementation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with severe cholestasis, a suggested starting dose is 17 to 35 mg/kg/day of RRR-alpha-tocopherol (25 to 50 international units/kg/day), with titration up if the ratio of alpha-tocopherol/total lipids does not normalize. Alternatively, water-miscible <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> can be used to maximize absorption, given at a dose of 10 to 17 mg/kg/day (15 to 25 international units/kg/day).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For adults with pancreatic disease or cholestasis, <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> requirements vary and supplements should be based on serum measurements of alpha-tocopherol. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence does not support a role for <a class="drug drug_general" data-topicid="10049" href="/d/drug information/10049.html" rel="external">vitamin E</a> supplementation in the prevention or treatment of cancers, cardiovascular and cerebrovascular disease, dementia, and retinopathy of prematurity. Weak evidence suggests a possible role in managing nonalcoholic fatty liver disease and in slowing the progression of macular degeneration and Alzheimer disease. In premature infants, vitamin E supplementation may reduce the risk of periventricular hemorrhage but also increases the risk of sepsis. (See <a class="local">'Potential benefits'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Evans HM, Bishop KS. ON THE EXISTENCE OF A HITHERTO UNRECOGNIZED DIETARY FACTOR ESSENTIAL FOR REPRODUCTION. Science 1922; 56:650.</a></li><li class="breakAll">Evans HM. The pioneer history of vitamin E. In: Vitamins and Hormones, Elsevier Science and Technology Books, Maryland Heights 1963. p.379.</li><li><a class="nounderline abstract_t">Nutrition classics from The Journal of Biological Chemistry 113:319-332, 1936. The isolation from wheat germ oil of an alcohol, alpha-tocopherol, having the properties of vitamin E. By Herbert M. Evans, Oliver H. Emerson, and Gladys A. Emerson. Nutr Rev 1974; 32:80.</a></li><li class="breakAll">Food and Nutrition Board of the Institute of Medicine. DRI Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. National Academies Press, Washington DC, 2000. p. 186. Available at: http://books.nap.edu/catalog.php?record_id=9810#toc (Accessed on October 01, 2018).</li><li><a class="nounderline abstract_t">Wolf G. How an increased intake of alpha-tocopherol can suppress the bioavailability of gamma-tocopherol. Nutr Rev 2006; 64:295.</a></li><li><a class="nounderline abstract_t">Huang HY, Appel LJ. Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans. J Nutr 2003; 133:3137.</a></li><li><a class="nounderline abstract_t">Burton GW, Joyce A, Ingold KU. Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch Biochem Biophys 1983; 221:281.</a></li><li><a class="nounderline abstract_t">Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328:1450.</a></li><li><a class="nounderline abstract_t">Jialal I, Fuller CJ, Huet BA. The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study. Arterioscler Thromb Vasc Biol 1995; 15:190.</a></li><li><a class="nounderline abstract_t">Hodis HN, Mack WJ, LaBree L, et al. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 273:1849.</a></li><li><a class="nounderline abstract_t">Stampfer MJ, Rimm EB. Epidemiologic evidence for vitamin E in prevention of cardiovascular disease. Am J Clin Nutr 1995; 62:1365S.</a></li><li><a class="nounderline abstract_t">Marchese ME, Kumar R, Colangelo LA, et al. The vitamin E isoforms α-tocopherol and γ-tocopherol have opposite associations with spirometric parameters: the CARDIA study. Respir Res 2014; 15:31.</a></li><li><a class="nounderline abstract_t">Abdala-Valencia H, Berdnikovs S, Cook-Mills JM. Vitamin E isoforms as modulators of lung inflammation. Nutrients 2013; 5:4347.</a></li><li><a class="nounderline abstract_t">Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci U S A 2000; 97:11494.</a></li><li><a class="nounderline abstract_t">Hernandez ML, Wagner JG, Kala A, et al. Vitamin E, γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers. Free Radic Biol Med 2013; 60:56.</a></li><li><a class="nounderline abstract_t">Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. Curr Med Chem 2004; 11:1113.</a></li><li><a class="nounderline abstract_t">Traber MG, Goldberg I, Davidson E, et al. Vitamin E uptake by human intestinal cells during lipolysis in vitro. Gastroenterology 1990; 98:96.</a></li><li><a class="nounderline abstract_t">Nakamura T, Aoyama Y, Fujita T, Katsui G. Studies on tocopherol derivatives: V. Intestinal absorption of several d,1-3,4-3H2-alpha-tocopheryl esters in the rat. Lipids 1975; 10:627.</a></li><li><a class="nounderline abstract_t">Cohn JS, McNamara JR, Cohn SD, et al. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988; 29:469.</a></li><li><a class="nounderline abstract_t">Cohn W, Loechleiter F, Weber F. Alpha-tocopherol is secreted from rat liver in very low density lipoproteins. J Lipid Res 1988; 29:1359.</a></li><li><a class="nounderline abstract_t">Yoshida H, Yusin M, Ren I, et al. Identification, purification, and immunochemical characterization of a tocopherol-binding protein in rat liver cytosol. J Lipid Res 1992; 33:343.</a></li><li><a class="nounderline abstract_t">Kalra V, Grover J, Ahuja GK, et al. Vitamin E deficiency and associated neurological deficits in children with protein-energy malnutrition. J Trop Pediatr 1998; 44:291.</a></li><li><a class="nounderline abstract_t">Kowdley KV. Lipids and lipid-activated vitamins in chronic cholestatic diseases. Clin Liver Dis 1998; 2:373.</a></li><li><a class="nounderline abstract_t">Jeffrey GP, Muller DP, Burroughs AK, et al. Vitamin E deficiency and its clinical significance in adults with primary biliary cirrhosis and other forms of chronic liver disease. J Hepatol 1987; 4:307.</a></li><li><a class="nounderline abstract_t">Muñoz SJ, Heubi JE, Balistreri WF, Maddrey WC. Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins. Hepatology 1989; 9:525.</a></li><li><a class="nounderline abstract_t">Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96:2745.</a></li><li class="breakAll">Lindor KD, Gershwin ME, Poupon R et al. AASLD Practice Guidelines, Primary Biliary Cirrhosis (2009). Available at: http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/PrimaryBillaryCirrhosis7-2009.pdf (Accessed on October 01, 2018).</li><li><a class="nounderline abstract_t">Ben Hamida M, Belal S, Sirugo G, et al. Friedreich's ataxia phenotype not linked to chromosome 9 and associated with selective autosomal recessive vitamin E deficiency in two inbred Tunisian families. Neurology 1993; 43:2179.</a></li><li><a class="nounderline abstract_t">Schuelke M, Mayatepek E, Inter M, et al. Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency. J Pediatr 1999; 134:240.</a></li><li><a class="nounderline abstract_t">El Euch-Fayache G, Bouhlal Y, Amouri R, et al. Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency. Brain 2014; 137:402.</a></li><li class="breakAll">Schuelke M. Ataxia with Vitamin E Deficiency. 2005 May 20 [Updated 2013 Jun 27]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1241/.</li><li><a class="nounderline abstract_t">van de Warrenburg BP, van Gaalen J, Boesch S, et al. EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood. Eur J Neurol 2014; 21:552.</a></li><li><a class="nounderline abstract_t">Di Donato I, Bianchi S, Federico A. Ataxia with vitamin E deficiency: update of molecular diagnosis. Neurol Sci 2010; 31:511.</a></li><li><a class="nounderline abstract_t">Kumar N. Nutritional neuropathies. Neurol Clin 2007; 25:209.</a></li><li><a class="nounderline abstract_t">Robinson MH, Dowling BL, Clark JV, Mason CH. Brown bowel syndrome: an unusual cause of massive dilatation of the colon. Gut 1989; 30:882.</a></li><li><a class="nounderline abstract_t">Białas M, Demczuk S, Dyduch G, et al. Brown bowel syndrome (intestinal lipofuscinosis) - a case report and review of the literature. Pol J Pathol 2013; 64:228.</a></li><li><a class="nounderline abstract_t">Oski FA, Barness LA. Vitamin E deficiency: a previously unrecognized cause of hemolytic anemia in the premature infant. J Pediatr 1967; 70:211.</a></li><li><a class="nounderline abstract_t">Natta C, Machlin L. Plasma levels of tocopherol in sickle cell anemia subjects. Am J Clin Nutr 1979; 32:1359.</a></li><li><a class="nounderline abstract_t">Ray D, Deshmukh P, Goswami K, Garg N. Antioxidant vitamin levels in sickle cell disorders. Natl Med J India 2007; 20:11.</a></li><li><a class="nounderline abstract_t">Walter PB, Fung EB, Killilea DW, et al. Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. Br J Haematol 2006; 135:254.</a></li><li><a class="nounderline abstract_t">Rachmilewitz EA, Shifter A, Kahane I. Vitamin E deficiency in beta-thalassemia major: changes in hematological and biochemical parameters after a therapeutic trial with alpha-tocopherol. Am J Clin Nutr 1979; 32:1850.</a></li><li><a class="nounderline abstract_t">Jaja SI, Aigbe PE, Gbenebitse S, Temiye EO. Changes in erythrocytes following supplementation with alpha-tocopherol in children suffering from sickle cell anaemia. Niger Postgrad Med J 2005; 12:110.</a></li><li class="breakAll">Feranchak AP, Sokol RJ. Medical and nutritional management of cholestasis in infants and children. In: Liver disease in children, 3rd ed, Suchy FJ, Sokol RJ, Balistreri WF (Eds), Cambridge University Press, New York 2007. p.213.</li><li><a class="nounderline abstract_t">Sokol RJ, Butler-Simon N, Conner C, et al. Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis. Gastroenterology 1993; 104:1727.</a></li><li><a class="nounderline abstract_t">Thébaut A, Nemeth A, Le Mouhaër J, et al. Oral Tocofersolan Corrects or Prevents Vitamin E Deficiency in Children With Chronic Cholestasis. J Pediatr Gastroenterol Nutr 2016; 63:610.</a></li><li class="breakAll">Sokol RJ. Vitamin E deficiency and neurological disorders. In: Vitamin E in Health and Disease, Packer L, Fuchs J (Eds), Marcel Dekker, New York 1992. p.815.</li><li><a class="nounderline abstract_t">Albahrani AA, Greaves RF. Fat-Soluble Vitamins: Clinical Indications and Current Challenges for Chromatographic Measurement. Clin Biochem Rev 2016; 37:27.</a></li><li><a class="nounderline abstract_t">Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005; 142:37.</a></li><li><a class="nounderline abstract_t">Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2012; :CD007176.</a></li><li><a class="nounderline abstract_t">Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011; 306:1549.</a></li><li><a class="nounderline abstract_t">Calzada C, Bruckdorfer KR, Rice-Evans CA. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 1997; 128:97.</a></li><li><a class="nounderline abstract_t">Dereska NH, McLemore EC, Tessier DJ, et al. Short-term, moderate dosage Vitamin E supplementation may have no effect on platelet aggregation, coagulation profile, and bleeding time in healthy individuals. J Surg Res 2006; 132:121.</a></li><li><a class="nounderline abstract_t">Kitagawa M, Mino M. Effects of elevated d-alpha(RRR)-tocopherol dosage in man. J Nutr Sci Vitaminol (Tokyo) 1989; 35:133.</a></li><li><a class="nounderline abstract_t">Pastori D, Carnevale R, Cangemi R, et al. Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. J Am Heart Assoc 2013; 2:e000364.</a></li><li><a class="nounderline abstract_t">Steiner M, Glantz M, Lekos A. Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks. Am J Clin Nutr 1995; 62:1381S.</a></li><li><a class="nounderline abstract_t">Corrigan JJ Jr, Ulfers LL. Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency. Am J Clin Nutr 1981; 34:1701.</a></li><li><a class="nounderline abstract_t">Finer NN, Peters KL, Hayek Z, Merkel CL. Vitamin E and necrotizing enterocolitis. Pediatrics 1984; 73:387.</a></li><li><a class="nounderline abstract_t">Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev 2017; 7:CD000254.</a></li><li><a class="nounderline abstract_t">Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database Syst Rev 2017; 7:CD000253.</a></li><li><a class="nounderline abstract_t">Brion LP, Bell EF, Raghuveer TS. Vitamin E supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2003; :CD003665.</a></li><li><a class="nounderline abstract_t">Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000; 71:630S.</a></li><li><a class="nounderline abstract_t">Farina N, Llewellyn D, Isaac MGEKN, Tabet N. Vitamin E for Alzheimer's dementia and mild cognitive impairment. Cochrane Database Syst Rev 2017; 4:CD002854.</a></li><li><a class="nounderline abstract_t">Soares-Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev 2018; 1:CD000209.</a></li></ol></div><div id="topicVersionRevision">Topic 2582 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17838496" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ON THE EXISTENCE OF A HITHERTO UNRECOGNIZED DIETARY FACTOR ESSENTIAL FOR REPRODUCTION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17838496" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : ON THE EXISTENCE OF A HITHERTO UNRECOGNIZED DIETARY FACTOR ESSENTIAL FOR REPRODUCTION.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4593257" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nutrition classics from The Journal of Biological Chemistry 113:319-332, 1936. The isolation from wheat germ oil of an alcohol, alpha-tocopherol, having the properties of vitamin E. By Herbert M. Evans, Oliver H. Emerson, and Gladys A. Emerson.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4593257" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nutrition classics from The Journal of Biological Chemistry 113:319-332, 1936. The isolation from wheat germ oil of an alcohol, alpha-tocopherol, having the properties of vitamin E. By Herbert M. Evans, Oliver H. Emerson, and Gladys A. Emerson.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16808116" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : How an increased intake of alpha-tocopherol can suppress the bioavailability of gamma-tocopherol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14519797" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Supplementation of diets with alpha-tocopherol reduces serum concentrations of gamma- and delta-tocopherol in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6830261" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8479464" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Vitamin E consumption and the risk of coronary heart disease in men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7749825" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The effect of alpha-tocopherol supplementation on LDL oxidation. A dose-response study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7776501" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7495232" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiologic evidence for vitamin E in prevention of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24629024" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The vitamin E isoformsα-tocopherol andγ-tocopherol have opposite associations with spirometric parameters: the CARDIA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24184873" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vitamin E isoforms as modulators of lung inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11005841" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23402870" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vitamin E,γ-tocopherol, reduces airway neutrophil recruitment after inhaled endotoxin challenge in rats and in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15134510" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Non-antioxidant activities of vitamin E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2293602" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vitamin E uptake by human intestinal cells during lipolysis in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1186449" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Studies on tocopherol derivatives: V. Intestinal absorption of several d,1-3,4-3H2-alpha-tocopheryl esters in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3392464" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Postprandial plasma lipoprotein changes in human subjects of different ages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3235918" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Alpha-tocopherol is secreted from rat liver in very low density lipoproteins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569384" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Identification, purification, and immunochemical characterization of a tocopherol-binding protein in rat liver cytosol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9819493" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Vitamin E deficiency and associated neurological deficits in children with protein-energy malnutrition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15560038" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lipids and lipid-activated vitamins in chronic cholestatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3036938" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vitamin E deficiency and its clinical significance in adults with primary biliary cirrhosis and other forms of chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2925155" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Vitamin E deficiency in primary biliary cirrhosis: gastrointestinal malabsorption, frequency and relationship to other lipid-soluble vitamins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11569705" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Fat-soluble vitamin levels in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11569705" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Fat-soluble vitamin levels in patients with primary biliary cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8232925" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Friedreich's ataxia phenotype not linked to chromosome 9 and associated with selective autosomal recessive vitamin E deficiency in two inbred Tunisian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9931538" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of ataxia in isolated vitamin E deficiency caused by alpha-tocopherol transfer protein deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24369383" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24369383" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Molecular, clinical and peripheral neuropathy study of Tunisian patients with ataxia with vitamin E deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24418350" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : EFNS/ENS Consensus on the diagnosis and management of chronic ataxias in adulthood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20464573" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ataxia with vitamin E deficiency: update of molecular diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17324726" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nutritional neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2753413" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Brown bowel syndrome: an unusual cause of massive dilatation of the colon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24166611" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Brown bowel syndrome (intestinal lipofuscinosis) - a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6066841" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Vitamin E deficiency: a previously unrecognized cause of hemolytic anemia in the premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/453051" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Plasma levels of tocopherol in sickle cell anemia subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17557515" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antioxidant vitamin levels in sickle cell disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17010049" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/474475" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Vitamin E deficiency in beta-thalassemia major: changes in hematological and biochemical parameters after a therapeutic trial with alpha-tocopherol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15997260" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Changes in erythrocytes following supplementation with alpha-tocopherol in children suffering from sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15997260" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Changes in erythrocytes following supplementation with alpha-tocopherol in children suffering from sickle cell anaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8500733" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Multicenter trial of d-alpha-tocopheryl polyethylene glycol 1000 succinate for treatment of vitamin E deficiency in children with chronic cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27429423" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Oral Tocofersolan Corrects or Prevents Vitamin E Deficiency in Children With Chronic Cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27429423" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Oral Tocofersolan Corrects or Prevents Vitamin E Deficiency in Children With Chronic Cholestasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27057076" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Fat-Soluble Vitamins: Clinical Indications and Current Challenges for Chromatographic Measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15537682" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419320" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21990298" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9051202" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The influence of antioxidant nutrients on platelet function in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16337968" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Short-term, moderate dosage Vitamin E supplementation may have no effect on platelet aggregation, coagulation profile, and bleeding time in healthy individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2732807" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effects of elevated d-alpha(RRR)-tocopherol dosage in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24166490" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7495235" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Vitamin E plus aspirin compared with aspirin alone in patients with transient ischemic attacks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7282596" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of vitamin E on prothrombin levels in warfarin-induced vitamin K deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6546616" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Vitamin E and necrotizing enterocolitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28756618" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28756617" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14583988" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vitamin E supplementation for prevention of morbidity and mortality in preterm infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10681271" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Vitamin E and Alzheimer disease: the basis for additional clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28418065" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Vitamin E for Alzheimer's dementia and mild cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29341067" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Vitamin E for antipsychotic-induced tardive dyskinesia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
